The protein therapeutics market totaled $63 billion in 2007 ($39 billion in the U.S. alone) and is expected to reach $87 billion by 2010, according to a report by Kalorama Information—“Protein ...

A problem for biopharmaceutical companies comes as degraded proteins lead to ineffective and possibly dangerous medicines for their clients. Drug companies work on formulation development to protect ...

An important parameter is the aggregation pattern when exposed to thermal stress, as this can give us a better understanding as needed for problem-solving during formulation development. To assess the ...

Forced degradation studies involve exposing a drug substance to harsher conditions than the product would be expected to experience and determining at what point and how it degrades. Identifying ...

This new Aramchol formulation was co-developed by Galmed and Barcode Nanotech, based on Barcode Nanotech's unique and proprietary platform which enables simultaneous screening of hundreds of different ...

WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, expanded its patent ...

WuXi Biologics, a leading global contract research, development, and manufacturing organization (CRDMO), announced the launch of WuXiHigh2.0, a high-throughput formulation development platform ...

Detailed price information for Galmed Pharmaceutica (GLMD-Q) from The Globe and Mail including charting and trades.